This technology includes the identification and use of heterocyclic alcohol compounds, including RITA and N-BIC, for the treatment of SULT1A1-expression cancers. A high-throughput screen (qHTS) was performed using >1,000 caner cell lines identified a compound called YC-1 (also called Lificiguat) that is effective across cancer cell types that express the phase 2 detoxifying enzyme SULT1A1.
Further clinical work with the YC-1 derivates could establish these heterocyclic alcohol compounds as therapies for SULT1A1 expressing cancers.
The identification of structurally related anti-cancer compounds is a novel treatment type for SULT1A1-expressing cancer cells. In addition, the work done to establish these compounds suggests that SULT1A1 expression may serve as a biomarker for patient selection.